Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China; Department of Gastric surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institutes of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.
Department of Gastric surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institutes of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou 310022, China; Zhejiang Provincial Research Center for Upper Gastrointestinal Tract Cancer, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Crit Rev Oncol Hematol. 2024 Dec;204:104541. doi: 10.1016/j.critrevonc.2024.104541. Epub 2024 Oct 24.
Despite recent advancements in the diagnosis and treatment options for cancer, it remains one of the most serious threats to health. Hyperthermia (HT) has emerged as a highly promising area of research due to its safety and cost-effectiveness. Currently, based on temperature, HT can be categorized into thermal ablation and mild hyperthermia. Thermal ablation involves raising the temperature within the tumor to over 60°C, resulting in direct necrosis in the central region of the tumor. In contrast, mild hyperthermia operates at relatively lower temperatures, typically in the range of 41-45°C, to induce damage to tumor cells. Furthermore, HT also serves as an immune adjuvant strategy in radiotherapy, chemotherapy, and immunotherapy, enhancing the effectiveness of radiotherapy, increasing the uptake of chemotherapy drugs, and reprogramming the tumor microenvironment through the induction of immunogenic cell death, thereby promoting the recruitment of endogenous immune cells. This article reviews the current status and development of hyperthermia, outlines potential mechanisms by which hyperthermia inhibits tumors, describes clinical trial attempts combining hyperthermia with radiotherapy, chemotherapy, and immunotherapy, and discusses the relationship between nanoparticles and hyperthermia.
尽管癌症的诊断和治疗选择在最近取得了进展，但它仍然是对健康最严重的威胁之一。由于其安全性和成本效益，热疗 (HT) 已成为一个极具前景的研究领域。目前，根据温度，HT 可分为热消融和轻度热疗。热消融涉及将肿瘤内的温度升高到 60°C 以上，导致肿瘤中心区域的直接坏死。相比之下，轻度热疗在相对较低的温度下进行，通常在 41-45°C 范围内，以诱导肿瘤细胞损伤。此外，HT 还作为放疗、化疗和免疫治疗的免疫佐剂策略，增强放疗的效果，增加化疗药物的摄取，并通过诱导免疫原性细胞死亡来重新编程肿瘤微环境，从而促进内源性免疫细胞的募集。本文综述了热疗的现状和发展，概述了热疗抑制肿瘤的潜在机制，描述了将热疗与放疗、化疗和免疫治疗相结合的临床试验尝试，并讨论了纳米粒子与热疗的关系。
